Karl-Christian Bergmann,1 Dirk Skowasch,2 Hartmut Timmermann,3 Robert Lindner,4 Johann Christian Virchow,5 Olaf Schmidt,6 Dirk Koschel,7 Claus Neurohr,8 Sebastian Heck,9 Katrin Milger10 1Institute for Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Berlin, Germany; 2Department of Internal Medicine II – Pneumology, University Hospital Bonn, Bonn, Germany; 3Schwerpunktpraxis Colonnaden, Hamburg, Germany; 4IQVIA Commercial GmbH & Co. OHG, Frankfurt Am Main, Germany; 5Universitätsmedizin Rostock - Zentrum für Innere Medizin, Medizinische Klinik I, Abteilung Pneumologie & Interdisziplinäre Internistische Intensivmedizin, Rostock, Germany; 6Pneumologische Gemeinschaftspraxis und Studienzentrum KPPK, Koblenz, Germany; 7Fachkrankenhaus Coswig, Lung Centre, Coswig, and Division of Pulmonology, Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany; 8Abteilung für Pneumologie und Beatmungsmedizin, Robert-Bosch-Krankenhaus Lungenzentrum, Stuttgart, Germany; 9GlaxoSmithKline GmbH & Co. KG, Munich, Germany; 10Department of Medicine V, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, GermanyCorrespondence: Karl-Christian Bergmann, Institute for Allergology-Charité, Luisenstraße 2, Berlin, 10117, Germany, Tel +491711934508, Fax +49 30 549090609, Email karlchristianbergmann@gmail.comPurpose: Asthma is one of the most prevalent chronic diseases in Germany affecting 4– 5% of all adults and 10% of children. Despite the availability of biologicals in recent years, studies show patients with inadequately controlled severe asthma in real life. The aim of the current study was to characterize and estimate the number of patients with NVL/GINA level 4 or 5 asthma and signs of poor control in Germany.Patients and Methods: In 2021, we retrospectively analyzed data ...